Alembic Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Alembic Pharmaceuticals's earnings have been declining at an average annual rate of -11%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 8.1% per year. Alembic Pharmaceuticals's return on equity is 13.2%, and it has net margins of 9.6%.

Key information

-11.0%

Earnings growth rate

-12.0%

EPS growth rate

Pharmaceuticals Industry Growth	17.5%
Revenue growth rate	8.1%
Return on equity	13.2%
Net Margin	9.6%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

May 05

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jan 17

Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

Dec 17

These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Sep 23

Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

Sep 02

Here's Why I Think Alembic Pharmaceuticals (NSE:APLLTD) Might Deserve Your Attention Today

Jun 16

Alembic Pharmaceuticals (NSE:APLLTD) Has A Pretty Healthy Balance Sheet

May 25

Revenue & Expenses Breakdown
Beta

How Alembic Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:APLLTD Revenue, expenses and earnings (INR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	61,181	5,902	13,484	0
30 Sep 23	59,966	5,317	12,904	0
30 Jun 23	58,766	5,285	12,332	0
31 Mar 23	56,526	3,420	11,755	0
31 Dec 22	56,619	2,113	11,540	0
30 Sep 22	54,246	2,662	11,354	0
30 Jun 22	52,419	3,153	11,335	0
31 Mar 22	53,058	5,209	11,382	0
31 Dec 21	51,704	7,609	10,951	0
30 Sep 21	52,131	8,771	10,848	0
30 Jun 21	53,778	10,412	10,678	0
31 Mar 21	53,931	11,465	10,514	0
31 Dec 20	53,196	11,521	10,639	0
30 Sep 20	52,144	10,937	10,283	0
30 Jun 20	49,982	10,066	9,699	0
31 Mar 20	46,058	8,288	9,094	0
31 Dec 19	43,259	7,282	8,941	0
30 Sep 19	41,349	6,638	8,656	0
30 Jun 19	40,211	6,176	8,305	0
31 Mar 19	39,347	5,844	7,773	0
31 Dec 18	38,604	5,542	7,176	0
30 Sep 18	36,823	5,149	6,667	0
30 Jun 18	33,445	4,364	6,436	0
31 Mar 18	31,302	4,126	6,372	0
31 Dec 17	29,894	4,119	6,188	0
30 Sep 17	29,264	3,678	6,207	0
30 Jun 17	30,165	3,661	5,833	0
31 Mar 17	31,052	4,032	5,737	0
31 Dec 16	30,130	3,999	4,774	4,159
30 Sep 16	31,584	5,828	4,644	3,693
30 Jun 16	32,942	7,515	4,648	3,386
31 Mar 16	31,232	7,200	4,867	0
31 Dec 15	30,185	6,986	7,878	2,265
30 Sep 15	26,086	4,998	7,499	1,869
30 Jun 15	21,469	2,881	7,128	1,400
31 Mar 15	20,579	2,829	3,159	1,216
31 Dec 14	20,167	2,739	6,470	1,223
30 Sep 14	19,906	2,692	6,184	1,208
30 Jun 14	19,303	2,535	5,781	1,236
31 Mar 14	18,642	2,355	5,498	1,164
31 Dec 13	17,770	2,179	4,689	1,072
30 Sep 13	16,610	2,002	4,542	999
30 Jun 13	15,809	1,811	4,435	822

Quality Earnings: APLLTD has high quality earnings.

Growing Profit Margin: APLLTD's current net profit margins (9.6%) are higher than last year (3.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: APLLTD's earnings have declined by 11% per year over the past 5 years.

Accelerating Growth: APLLTD's earnings growth over the past year (179.3%) exceeds its 5-year average (-11% per year).

Earnings vs Industry: APLLTD earnings growth over the past year (179.3%) exceeded the Pharmaceuticals industry 23.8%.

Return on Equity

High ROE: APLLTD's Return on Equity (13.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Alembic Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Key information

Recent past performance updates

Third quarter 2024 earnings: Revenues in line with analyst expectations

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Recent updates

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Third quarter 2024 earnings: Revenues in line with analyst expectations

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Investor sentiment improves as stock rises 17%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals

Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy

Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel

Price target increased by 10% to ₹659

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Upcoming dividend of ₹8.00 per share at 1.2% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Consensus EPS estimates fall by 19%

Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022)

Consensus EPS estimates fall by 11%

Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05%

Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w

Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg

Consensus forecasts updated

Insufficient new directors

Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Investor sentiment improved over the past week

Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G

Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration

Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara

Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022

Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg

Consensus EPS estimates fall by 28%

Upcoming dividend of ₹10.00 per share

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Price target decreased to ₹734

First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022)

Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Pirfenidone Tablets

Alembic Pharmaceuticals Limited Announces USFDA Final Approval for Arformoterol Tartrate Inhalation Solution, 15 Mcg (Base)/2 ML Unit-Dose Vial

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Alembic Pharmaceuticals Limited to Report Q4, 2022 Results on May 02, 2022

Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg

Alembic Pharmaceuticals Limited Receives Tentative Approval from US Food & Drug Administration for Dabigatran Etexilate Capsules, 75 Mg, 110 Mg, and 150 Mg

Alembic Pharmaceuticals Limited (NSEI:APLLTD) acquired remaining 40% stake in Aleor Dermaceuticals Limited from Orbicular Pharmaceutical Technologies Private Limited.

Revenue & Expenses Breakdown
Beta